FGFR (Fibroblast growth factor receptors) are the receptors that bind to members of the fibroblast growth factor family of proteins.Pathological conditions involve some of these receptors. Achondroplasia can be brought on by a point mutation in FGFR3. Vertebrates have been found to contain five distinct membrane FGFRs, all of which are members of the tyrosine kinase superfamily (FGFR1, FGFR2, FGFR3, FGFR4, FGFR6). One of the most significant families of paracrine factors that function in the development process is the fibroblast growth factor family. They control which cells differentiate into mesoderm, the production of blood vessels, the growth of limbs, and the growth and differentiation of many different cell types.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V3276 | ACTB-1003 | 939805-30-8 | ACTB-1003 is an orally available multi-kinase inhibitorwithIC50values of 6, 2 and 4 nM forFGFR1,VEGFR2andTie-2. |
|
V5247 | Alofanib (RPT835) | 1612888-66-0 | Alofanib (known aslso as RPT835) is a novel, potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2) with anticancer and antiangiogenic activity. |
|
V5222 | ASP-5878 | 1453208-66-6 | ASP5878 is a novel, potent,selective and orally bioactive inhibitor of FGFR 1, 2, 3, and 4, with IC50values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity. |
|
V2693 | BLU-554(BLU-554) | 1707289-21-1 | BLU-554 is a novel potent, highly-selective, and orally bioavailable inhibitor of FGFR4 (fibroblast growth factor receptor 4) with an IC50 value of 5 nM in cell free assays. |
|
V0617 | BLU9931 | 1538604-68-0 | BLU9931 (BLU-9931; BLU 9931) is an irreversible and selective FGFR4 inhibitor with potential anticancer activity. |
|
V37655 | BO-264 | 2408648-20-2 | BO-264 is a novel and orally bioactive transforming acidic coiled-coil 3 (TACC3) inhibitor with an IC50 of 188 nM and a Kd of 1.5 nM. |
|
V0618 | CH5183284 (FF-284; Debio-1347) | 1265229-25-1 | CH5183284 (also known as FF284; Debio-1347) is a novel, potent, selective and orally bioavailable FGFR inhibitor with potential antitumor activity. |
|
V69468 | CPL304110 | 1627826-19-0 | CPL304110 is a potent, orally bioavailable, and selective inhibitor of the fibroblast growth factor receptor FGFR (1-3) with IC50s of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3). |
|
V3693 | Derazantinib (ARQ-087) | 1234356-69-4 | Derazantinib (formerly known as ARQ 087) is a novel, orally bioavailable, ATP competitive, small molecule, multi-kinase inhibitor with potent in vitro and in vivo activity against FGFR (fibroblast growth factor receptor) addicted cell lines and tumors withIC50s of 4.5, 1.8, and 4.5 nM forFGFR1-3 respectively in biochemical assay, IC50 values of 1.8 nM for FGFR2, and 4.5 nM for FGFR1 and 3. |
|
V3694 | Derazantinib racemate | 2309668-44-6 | Derazantinib Racemate is the racemic mixture of derazantinib which is formerly known as ARQ 087 and is a novel, orally bioavailable, ATP competitive, small molecule, multi-kinase inhibitor with potent in vitro and in vivo activity against FGFR (fibroblast growth factor receptor) addicted cell lines and tumors withIC50s of 4.5, 1.8, and 4.5 nM forFGFR1-3 respectively in biochemical assay, IC50 values of 1.8 nM for FGFR2, and 4.5 nM for FGFR1 and 3. |
|
V69485 | Efruxifermin | 2375240-92-7 | Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to modified human FGF21). |
|
V69465 | Fazpilodemab (BFKB8488A) | 2517935-02-1 | Fazpilodemab (BFKB8488A) is a humanized, agonistic bispecific antibody targeting fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. |
|
V0616 | Fexagratinib (AZD-4547; ADSK-091) | 1035270-39-3 | AZD4547 (AZD-4547; AZD 4547) is a novel and orally bioavailable FGFR (fibroblast growth factor receptor) inhibitor with potential antineoplastic activity. |
|
V69458 | FGFR-IN-1 | 1513860-41-7 | FGFR-IN-1 is a potent FGFR inhibitor (antagonist) with IC50 of less than 100 nM for FGFR1, FGFR2 and FGFR3 respectively. |
|
V69466 | FGFR-IN-11 | 2658488-68-5 | FGFR-IN-11 (compound I-5) is an orally bioactive and covalent pan-FGFR inhibitor (antagonist) with IC50s of 9.9 nM (FGFR1), 3.1 nM (FGFR2), 16 nM (FGFR3) and 1.8 respectively. |
|
V69464 | FGFR-IN-12 | 943189-02-4 | FGFR-IN-12 (example 14) is a pyrimidinyl aryl urean analogue and a potent FGFR inhibitor. |
|
V78857 | FGFR-IN-9 | FGFR-IN-9 (Compound 19) is a potent, reversible, orally bioactive FGFR inhibitor (antagonist) with IC50s of 17.1, 29.6, 30.7, 46.7, and 64.3 nM for FGFR4WT, FGFR3, FGFR4V550L, FGFR2, and FGFR1, respectively. | |
|
V78963 | FGFR1 inhibitor 7 | FGFR1 inhibitor 7 (compound 5) is an inhibitor (blocker/antagonist) of FGFR1 tyrosine kinase with IC50 of 0.33 nM. | |
|
V69473 | FGFR1 inhibitor-10 | 2426769-76-6 | FGFR1 inhibitor-10 (Compound 4i) is an FGFR1 inhibitor (IC50= 28 nM). |
|
V69471 | FGFR1 inhibitor-2 | 2410612-08-5 | FGFR1 inhibitor-2 is an FGFR1 inhibitor (IC50 is 4.55 μM in MDA-MB-231 cells). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
